The National Health Service (NHS) is preparing to introduce an innovative artificial intelligence (AI)-powered blood test that could significantly change how women are assessed for possible womb cancer. The technology aims to help healthcare professionals identify women at very low risk of cancer before they undergo invasive diagnostic procedures, potentially improving patient experience while easing pressure on NHS diagnostic services.
The new test, developed by Leeds-based PinPoint Data Science, uses machine learning technology to analyze blood samples and estimate a patient’s likelihood of having cancer. Several NHS hospitals are now preparing to integrate the test into existing cancer referral pathways following encouraging trial results.
As healthcare systems around the world increasingly adopt AI-driven technologies, this development represents another important step toward faster, more efficient, and less invasive cancer diagnostics.
Growing Need for Better Womb Cancer Assessment
Womb cancer, also known as endometrial cancer, is one of the most common cancers affecting women in the United Kingdom. Early diagnosis remains crucial because treatment outcomes are generally better when the disease is detected at an earlier stage.
Every year, approximately 90,000 postmenopausal women in England are referred by general practitioners (GPs) for further investigation after experiencing heavy or unusual bleeding. While these symptoms can be associated with several non-cancerous conditions, they are also recognized as potential warning signs of womb cancer.
Of those women referred for specialist assessment, around 10,000 are ultimately diagnosed with womb cancer annually. Sadly, approximately 2,700 women die from the disease each year.
These figures highlight a significant challenge faced by healthcare providers: the majority of women referred for testing do not have cancer, yet they must often undergo a series of uncomfortable and invasive diagnostic procedures before cancer can be ruled out.
The introduction of an AI-powered blood test could help address this issue by providing clinicians with an additional tool to evaluate cancer risk earlier in the diagnostic process.
Understanding the PinPoint AI Blood Test
The new blood test has been developed by PinPoint Data Science, a healthcare technology company based in Leeds. The company specializes in using machine learning and advanced data analytics to support cancer diagnosis and patient triage.
The test works by examining approximately 30 blood-based markers. These biomarkers are analyzed using machine learning algorithms that have been trained to recognize patterns associated with cancer risk.
Rather than providing a simple positive or negative result, the system generates a risk score that places patients into one of three categories:
- Low risk
- Elevated risk
- High risk
This risk classification can then be used by clinicians alongside existing medical assessments to determine the most appropriate next steps for each patient.
According to PinPoint, the test costs approximately £30 per patient, making it a relatively affordable addition to current diagnostic pathways.
The company emphasizes that the tool is designed to complement—not replace—existing clinical decision-making processes. Healthcare professionals can use the results to decide whether a patient should be monitored, referred for further investigation, or prioritized for faster specialist assessment.
A Multi-Cancer Detection Approach
One notable feature of the PinPoint technology is that it is not limited to womb cancer detection.
The company describes the system as a multi-cancer testing platform capable of supporting assessment across several cancer pathways, including:
- Gynaecological cancers
- Lung cancer
- Upper gastrointestinal cancers
- Head and neck cancers
- Lower gastrointestinal cancers
This broader application could increase the overall value of the technology within the NHS by allowing a single testing platform to assist clinicians across multiple specialties.
As healthcare organizations continue to search for ways to improve efficiency and reduce diagnostic waiting times, tools that can be applied across several cancer pathways may become increasingly important.
Large-Scale Trial Demonstrated Strong Results
The NHS rollout follows a major trial involving 16,481 patients who had been referred through urgent suspected cancer pathways across Yorkshire.
The study included women who had symptoms suggesting possible womb cancer or other gynaecological cancers.
According to the reported findings, approximately one in ten women referred because of heavy bleeding were eventually diagnosed with cancer.
The trial results demonstrated impressive performance from the AI-powered blood test.
PinPoint reported that the system successfully identified 99.1% of cancer cases as either elevated risk or high risk.
In addition, the lowest-risk group achieved a negative predictive value of 99.8%.
A negative predictive value measures how reliably a test can identify individuals who do not have the disease. A figure of 99.8% suggests that women classified as low risk were extremely unlikely to have cancer.
These findings have generated interest among healthcare professionals seeking safer and more efficient ways to assess patients before invasive investigations are performed.
NHS Trusts Preparing to Implement the Technology
Several NHS organizations are already planning to integrate the PinPoint test into their cancer assessment pathways.
Mid Yorkshire NHS Teaching Trust intends to use the technology across six different gynaecological and upper gastrointestinal cancer pathways.
Meanwhile, Leeds Teaching Hospitals NHS Trust plans to adopt the test specifically for gynaecological cancer assessments.
The implementation of the test at these institutions represents an important real-world evaluation of how AI-assisted diagnostics can function within everyday NHS clinical practice.
If successful, wider adoption across England could follow in the coming years.
Current Diagnostic Process for Suspected Womb Cancer
To understand the potential impact of the new blood test, it is important to examine the current diagnostic pathway.
Women referred for suspected reproductive system cancers generally undergo a pelvic examination as part of their assessment.
A key component of this process is often a transvaginal ultrasound scan.
During this procedure, an ultrasound probe is inserted into the vagina to obtain detailed images of the reproductive organs and measure the thickness of the womb lining.
Although clinically valuable, some women report that the examination can be uncomfortable, distressing, or painful.
If healthcare professionals remain concerned about the possibility of cancer after the scan, further investigations may be required.
These can include:
Biopsy
A biopsy involves removing a small tissue sample from the womb lining so it can be examined under a microscope.
Hysteroscopy
A hysteroscopy allows doctors to visually inspect the inside of the womb using a thin instrument equipped with a camera.
While these procedures play a critical role in diagnosing cancer, they can cause anxiety and discomfort for patients.
Consequently, there is strong interest in identifying safe methods to reduce unnecessary invasive investigations.
How the AI Blood Test Could Reduce Invasive Procedures
The primary goal of the PinPoint blood test is to identify women who are at extremely low risk of cancer before they undergo more invasive assessments.
According to the company, the technology could potentially spare around one in five referred women from needing a transvaginal ultrasound scan.
Based on current referral figures, this could mean approximately 18,000 women each year in England avoiding the procedure.
For many patients, this would represent a substantial improvement in their healthcare experience.
Beyond patient comfort, reducing unnecessary investigations could also generate significant operational benefits for NHS services.
Diagnostic departments often face heavy workloads and long waiting lists. By identifying low-risk patients earlier, healthcare providers may be able to allocate resources more efficiently and prioritize those who require urgent specialist assessment.
Expert Views on the Technology
Healthcare professionals involved with the project have highlighted several potential benefits.
Professor Sean Duffy, Chief Medical Officer at PinPoint Data Science and former National Clinical Director for Cancer at NHS England, emphasized the value of accurately ruling out women who are at very low risk of cancer.
In cancer diagnostics, identifying patients who are unlikely to have disease can be just as important as identifying those who do.
Reducing unnecessary testing allows healthcare systems to focus resources where they are most needed.
Dr. Jacinta Walsh, a GP at King’s Medical Practice in Normanton, West Yorkshire, noted that some patients may require as many as six GP appointments before cancer can be confidently ruled out.
She suggested that the blood test could accelerate decision-making and reduce the number of consultations required.
By streamlining the diagnostic pathway, clinicians could potentially free up valuable appointment capacity for other patients.
Improving Patient Experience
One of the strongest arguments for adopting the AI blood test relates to patient experience.
Many women referred for suspected cancer face considerable stress while waiting for diagnostic procedures and results.
Even when cancer is ultimately ruled out, the process can involve multiple appointments, scans, and invasive examinations.
Tracy Jackson, Consultant Gynaecologist and Cancer Unit Lead at Leeds Teaching Hospitals NHS Trust, pointed out that most women referred through current pathways do not actually have cancer.
Nevertheless, they often undergo investigations that may be uncomfortable or emotionally challenging.
She believes the blood test could help clinicians triage patients more effectively before hospital-based investigations are arranged.
Women classified as low risk could potentially be reassured earlier, while those with higher risk scores could receive faster access to specialist testing.
This approach may improve both patient satisfaction and clinical efficiency.
AI Adoption Across the NHS Continues to Expand
The PinPoint blood test is just one example of the NHS’s growing use of artificial intelligence technologies.
Several other AI-driven initiatives are already being implemented across England.
MEMORI at Kent and Canterbury Hospital
East Kent Hospitals University NHS Foundation Trust is using an AI system known as MEMORI to evaluate infection risk among patients.
The platform analyzes information already contained within routine patient records, including:
- Blood test results
- Blood pressure readings
- Temperature measurements
- Clinical observations
- Medication records
- Demographic information
By processing this data, the system helps clinicians identify patients who may require additional attention.
AI Triage Tool in the NHS App
NHS England is also deploying an AI-powered triage system through the NHS App.
The organization expects the service to reach more than 200,000 patients within the next 12 months.
Plans are in place to make the tool available to all NHS App users by April 2028.
The technology is designed to guide patients toward appropriate healthcare services while helping manage demand across the healthcare system.
AI-Powered Chest X-Ray Analysis
Another major initiative involves AI-assisted chest X-ray interpretation for suspected lung cancer cases.
The UK government has committed £20 million to expand the technology to every NHS trust in England by 2029.
The tools are already available in approximately half of NHS trusts and have supported the assessment of more than four million patients undergoing investigation for lung cancer.
These projects demonstrate the NHS’s broader commitment to integrating AI into clinical workflows to improve efficiency, support decision-making, and enhance patient outcomes.
More Research Still Needed
Despite the encouraging trial results, experts caution that further evidence will be necessary before the full impact of the PinPoint test can be determined.
Researchers will need to evaluate how the test affects several important factors, including:
- Patient outcomes
- Referral decisions
- Diagnostic accuracy
- Waiting times
- NHS resource utilization
- Overall healthcare costs
Large-scale implementation studies will help establish whether the technology delivers the anticipated benefits in real-world clinical settings.
As with any new healthcare innovation, ongoing monitoring and evaluation will remain essential.
Cancer Research UK Calls the Technology Promising
Cancer Research UK has described the PinPoint blood test as a promising development while emphasizing the need for additional research.
The charity acknowledged that earlier cancer detection saves lives and noted that many patients are not currently diagnosed quickly enough.
According to Samantha Harrison, a spokesperson for the organization, the blood test could potentially help rule out endometrial cancer in some women without requiring further invasive investigations.
However, the charity stressed that additional evidence is needed to fully understand how the technology will benefit patients and the NHS.
This balanced perspective reflects the cautious optimism shared by many healthcare experts regarding AI-powered diagnostic tools.
The Future of AI in Cancer Detection
Artificial intelligence is increasingly becoming a key component of modern healthcare, particularly in cancer detection and diagnosis.
The PinPoint blood test illustrates how machine learning can assist clinicians in making more informed decisions while reducing unnecessary procedures for patients.
If future studies continue to validate the technology’s performance, it could become an important addition to cancer referral pathways across England.
For thousands of women each year, this may mean fewer invasive examinations, faster reassurance when cancer is unlikely, and quicker access to specialist care when concerns are identified.
While further research remains necessary, the early results suggest that AI-powered blood testing could play a significant role in the future of womb cancer assessment and broader cancer diagnostics within the NHS.
As healthcare systems continue to seek innovative solutions for improving efficiency and patient care, technologies like the PinPoint test may help shape a more precise, patient-centered approach to cancer detection in the years ahead.
Image Credit unsplash
Discover more from AiTechtonic - Informative & Entertaining Text Media
Subscribe to get the latest posts sent to your email.